Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has scheduled a significant announcement combining two key updates. The company will release topline results from the RADIANT trial of vormatrigine along with its Q2 2025 financial results before market open on August 4, 2025.
The company will host a live webcast at 8:30 AM ET on the same day to discuss these results. Investors can access the webcast through a registration link or the company's website, with a replay available for 90 days following the event.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi del SNC, ha programmato un annuncio importante che combina due aggiornamenti chiave. La società pubblicherà i risultati principali dello studio RADIANT sul vormatrigine insieme ai risultati finanziari del secondo trimestre 2025 prima dell'apertura dei mercati il 4 agosto 2025.
Lo stesso giorno, alle 8:30 AM ET, si terrà una webcast in diretta per discutere di questi risultati. Gli investitori potranno accedere alla trasmissione tramite un link di registrazione o dal sito web dell'azienda, con la possibilità di rivederla per 90 giorni dopo l'evento.
Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmacéutica en etapa clínica enfocada en trastornos del SNC, ha programado un anuncio importante que combina dos actualizaciones clave. La compañía publicará los resultados principales del ensayo RADIANT de vormatrigine junto con sus resultados financieros del segundo trimestre de 2025 antes de la apertura del mercado el 4 de agosto de 2025.
La empresa realizará una transmisión en vivo a las 8:30 AM ET el mismo día para discutir estos resultados. Los inversionistas podrán acceder a la transmisión mediante un enlace de registro o en el sitio web de la compañía, con una repetición disponible durante 90 días después del evento.
Praxis Precision Medicines (NASDAQ: PRAX)는 중추신경계 질환에 중점을 둔 임상 단계의 바이오제약 회사로, 두 가지 주요 업데이트를 결합한 중요한 발표를 예정하고 있습니다. 회사는 vormatrigine의 RADIANT 시험 주요 결과와 함께 2025년 2분기 재무 결과를 2025년 8월 4일 장 개장 전 공개할 예정입니다.
같은 날 오전 8시 30분(동부시간)에 이 결과를 논의하는 라이브 웹캐스트를 진행합니다. 투자자들은 등록 링크나 회사 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이벤트 후 90일 동안 다시보기가 제공됩니다.
Praxis Precision Medicines (NASDAQ : PRAX), une société biopharmaceutique en phase clinique spécialisée dans les troubles du système nerveux central, a programmé une annonce importante combinant deux mises à jour clés. La société publiera les résultats principaux de l'essai RADIANT sur le vormatrigine ainsi que ses résultats financiers du deuxième trimestre 2025 avant l'ouverture des marchés le 4 août 2025.
Le même jour, à 8h30 (heure de l'Est), un webcast en direct sera organisé pour discuter de ces résultats. Les investisseurs pourront accéder au webcast via un lien d'inscription ou sur le site web de la société, avec une rediffusion disponible pendant 90 jours après l'événement.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf ZNS-Erkrankungen, hat eine wichtige Ankündigung geplant, die zwei zentrale Updates kombiniert. Das Unternehmen wird die Hauptergebnisse der RADIANT-Studie zu Vormatrigin sowie die Finanzergebnisse für das zweite Quartal 2025 vor Markteröffnung am 4. August 2025 veröffentlichen.
Am selben Tag wird um 8:30 Uhr ET ein Live-Webcast stattfinden, um diese Ergebnisse zu besprechen. Investoren können über einen Registrierungslink oder die Website des Unternehmens auf den Webcast zugreifen, mit einer Wiedergabeoption für 90 Tage nach der Veranstaltung.
- None.
- None.
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025.
The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors daniel@lifesciadvisors.com 617-430-7576
FAQ
When will Praxis Precision Medicines (PRAX) release its Q2 2025 earnings and RADIANT trial results?
What time is the Praxis Precision Medicines (PRAX) earnings and trial results webcast?
How can investors access the Praxis Precision Medicines (PRAX) RADIANT trial results webcast?
What is the RADIANT trial by Praxis Precision Medicines studying?
How long will the Praxis Precision Medicines (PRAX) webcast replay be available?
